<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501928</url>
  </required_header>
  <id_info>
    <org_study_id>A0221109</org_study_id>
    <nct_id>NCT02501928</nct_id>
  </id_info>
  <brief_title>Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.</brief_title>
  <official_title>Long-term Extension Study To Evaluate The Safety Of Fesoterodine In Japanese Pediatric Subjects With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity) Who Have Completed 24 Weeks Treatment In Study A0221047</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of fesoterodine
      following once daily long-term treatment in Japanese pediatric neurogenic detrusor
      overactivity (NDO) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multi-center, open-label long-term extension study in Japanese NDO
      subjects who participated and completed in the precedent Study A0221047 which is a 24 weeks,
      randomized, open label study, to investigate the safety and tolerability of fesoterodine.

      This study consists of a 28-week open-label treatment period followed by a 4-week follow-up.
      In addition, subjects in the oxybutynin arm of the precedent Study A0221047 will continue the
      fesoterodine treatment until Week 40 visit in this study, in order to obtain fesoterodine 1
      year treatment data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2015</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>28 or 40 weeks</time_frame>
    <description>Adverse events, including monitoring of targeted events including, but not limited to; serious adverse event, anticholinergic effects, CNS effects and visual effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visual acuity from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in accommodation from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
    <description>Accommodation will be assessed by the push up test to assess minimum focusing distance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cognitive function from baseline by the Child Behavior Checklist and Grooved Pegboard Test</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in temperature from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pulse rate from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of urinary tract infection</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clinical laboratory (hematology) from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clinical laboratory (chemistry) from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clinical laboratory (urinalysis) from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in post-void residual volume from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in maximum cystometric bladder capacity (Urodynamics assessment) from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in detrusor pressure at maximum bladder capacity (Urodynamics assessment)</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of involuntary detrusor contractions (Urodynamics assessment)</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bladder volume at first involuntary detrusor contraction (Urodynamics assessment) from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bladder compliance (Urodynamics assessment) from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of micturitions and/or catheterizations/24 hours from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of incontinence episodes/24 hours from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean urgency episodes/24 hours from baseline, if applicable</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean volume voided per micturition or mean volume per catheterization from baseline</measure>
    <time_frame>28 or 40 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Urinary Bladder, Neurogenic</condition>
  <arm_group>
    <arm_group_label>Fesoterodine PR 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine BIC 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine BIC 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 4 mg</intervention_name>
    <description>Fesoterodine 4 mg tablet once daily for 28 or 40 weeks</description>
    <arm_group_label>Fesoterodine PR 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 8 mg</intervention_name>
    <description>Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks</description>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine BIC 2 mg</intervention_name>
    <description>Fesoterodine BIC 2 mg tablet once daily for 28 weeks</description>
    <arm_group_label>Fesoterodine BIC 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine BIC 4 mg</intervention_name>
    <description>Fesoterodine BIC 4 mg tablet once daily for 28 weeks</description>
    <arm_group_label>Fesoterodine BIC 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢Subjects who completed 24 week treatment and all visit procedures in the precedent Study
        A0221047

        Exclusion Criteria:

          -  Subjects who had major protocol violation (as determined by the Sponsor) in Study
             A0221047

          -  Concomitant medications which may increase the risk to subjects or confound study
             results

          -  Other medical conditions which may increase the risk to subjects or confound study
             results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital</name>
      <address>
        <city>Izumi-shi</city>
        <state>Osaka</state>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Aoiku Shizuokashi</city>
        <state>Shizuoka</state>
        <zip>420 8660</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Shimotsuga-gun</city>
        <state>Tochigi</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221109&amp;StudyName=Long-term%20Extension%20Study%20To%20Evaluate%20The%20Safety%20Of%20Fesoterodine%20In%20Japanese%20Pediatric%20Subjects%20With%20Symptoms%20Of%20Detrusor%20Overactivity%20Associated%20With%20A%20Neurological%20Condition%20%28neurogenic%20Detrusor%20Overactivity%29%20Who%20Have%20Completed%2024%20Weeks%20Treatment%20In%20Study%20A0221047</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurogenic detrusor overactivity</keyword>
  <keyword>fesoterodine</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

